Evidence map›Paper›PMID 38480681›Full record

ArticleNature communications2024

High-resolution cryo-EM of the human CDK-activating kinase for structure-based drug design.

Victoria I Cushing, Adrian F Koh, Junjie Feng, Kaste Jurgaityte, Alexander Bondke, Sebastian H B Kroll, Marion Barbazanges, Bodo Scheiper, Ash K Bahl, Anthony G M Barrett and 3 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
23.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 44 citations in OpenAlex.

  1. Structural basis for P-TEFb association with BRD4.bioRxiv : the preprint server for biology · 2026
    Article
  2. Review
  3. Review
  4. Targeting CDKs in the RNAPII transcription cycle.Nature reviews. Drug discovery · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. CDK7 as a Target for Docking Screens.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Target Engagement Assays in Early Drug Discovery.Journal of medicinal chemistry · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Victoria I CushingThe Institute of Cancer Research, Chester Beatty Laboratories, 237 Fulham Road, London, SW3 6JB, UK.ORCID 0000-0002-7976-0859
Adrian F KohMaterials and Structural Analysis Division, Thermo Fisher Scientific, Achtseweg Noord 5, 5651, Eindhoven, The Netherlands.ORCID 0000-0001-6682-4449
Junjie FengThe Institute of Cancer Research, Chester Beatty Laboratories, 237 Fulham Road, London, SW3 6JB, UK.
Kaste JurgaityteDivision of Cancer, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK.ORCID 0009-0004-4356-6677
Alexander BondkeDepartment of Chemistry, Imperial College London, London, UK.
Sebastian H B KrollDepartment of Chemistry, Imperial College London, London, UK.
Marion BarbazangesDepartment of Chemistry, Imperial College London, London, UK.ORCID 0000-0002-1511-6538
Bodo ScheiperDepartment of Chemistry, Imperial College London, London, UK.
Ash K BahlCarrick Therapeutics, Nova UCD, Bellfield Innovation Park, Dublin 4, Ireland.
Anthony G M BarrettDepartment of Chemistry, Imperial College London, London, UK.ORCID 0000-0002-8485-215X
Simak AliDivision of Cancer, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK. simak.ali@imperial.ac.uk.ORCID 0000-0002-1320-0816
Abhay KotechaMaterials and Structural Analysis Division, Thermo Fisher Scientific, Achtseweg Noord 5, 5651, Eindhoven, The Netherlands. abhay.kotecha@thermofisher.com.ORCID 0000-0002-4480-5439
Basil J GreberThe Institute of Cancer Research, Chester Beatty Laboratories, 237 Fulham Road, London, SW3 6JB, UK. basil.greber@icr.ac.uk.ORCID 0000-0001-9379-7159
Imperial College London · GBInstitute of Cancer Research · GBHammersmith Hospital · GBThermo Fisher Scientific (Netherlands) · NLCentre National de la Recherche Scientifique · FR

Funding

Cancer Research UK (CRUK) C37/A12011Cancer Research UK (CRUK) C37/A18784Cancer Research UK (CRUK) C37/A9335RCUK | Medical Research Council (MRC) MR/V009354/1
6 · The paper itself

Abstract

Rational design of next-generation therapeutics can be facilitated by high-resolution structures of drug targets bound to small-molecule inhibitors. However, application of structure-based methods to macromolecules refractory to crystallization has been hampered by the often-limiting resolution and throughput of cryogenic electron microscopy (cryo-EM). Here, we use high-resolution cryo-EM to determine structures of the CDK-activating kinase, a master regulator of cell growth and division, in its free and nucleotide-bound states and in complex with 15 inhibitors at up to 1.8 Å resolution. Our structures provide detailed insight into inhibitor interactions and networks of water molecules in the active site of cyclin-dependent kinase 7 and provide insights into the mechanisms contributing to inhibitor selectivity, thereby providing the basis for rational design of next-generation therapeutics. These results establish a methodological framework for the use of high-resolution cryo-EM in structure-based drug design.

Indexed as

Cyclin-Dependent Kinase-Activating KinaseDrug DesignCell CycleCryoelectron MicroscopyHumansMacromolecular SubstancesCyclin-Dependent Kinase-Activating KinaseMacromolecular Substances

Identifiers

PMID38480681
PMCPMC10937634
OpenAlexW4392762297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.